Eplerenone Improved Hypokalemia in a Patient with Gitelman's Syndrome
Eplerenone Improved Hypokalemia in a Patient with Gitelman's Syndrome
复制标题
DOI：
10.2169/internalmedicine.51.5723
复制
发表时间：
2012-01-01
影响因子：
1.2
通讯作者：
Oiso, Yutaka
中科院分区：
文献类型：
--
作者：
Ito, Yukiko;Yoshida, Masanori;Oiso, Yutaka
一名47岁女性出现低钾血症（2.4 mmol/L）。她还患有低镁血症、低钙尿症和高肾素性高醛固酮症。序列分析发现SLC 12 A3基因存在R655 C和R955 Q复合杂合突变。这些结果与Gitelman综合征（GS）一致。依普利酮是一种选择性醛固酮阻断剂，与口服氯化钾联合使用可改善血清钾水平（3.6 mmol/L），无明显不良反应。虽然依普利酮对醛固酮受体的选择性亲和力优于螺内酯，但依普利酮治疗GS的疗效和安全性尚不清楚。我们的观察结果表明，依普利酮是一个有用的治疗选择GS。
A 47-year-old woman presented with hypokalemia (2.4 mmol/L). She also had hypomagnesemia, hypocalciuria, and hyperreninemic hyperaldosteronism. Sequence analysis revealed a compound heterozygous mutation, R655C and R955Q, in the SLC12A3 gene. These findings were compatible with Gitelman's syndrome (GS). Eplerenone, a selective aldosterone blocker, in combination with oral potassium chloride improved serum potassium level (3.6 mmol/L) with no apparent adverse effect. Although eplerenone has an advantage over spironolactone for its selective affinity for the aldosterone receptor, the efficacy and safety of eplerenone for GS is little understood. Our observation suggests that eplerenone is a useful treatment option for GS.